Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas.

dc.contributor.author
Potrony Mateu, Míriam
dc.contributor.author
Badenas Orquin, Celia
dc.contributor.author
Naerhuyzen, Bénédicte
dc.contributor.author
Aguilera, Paula
dc.contributor.author
Puig Butillé, Joan Anton
dc.contributor.author
Tell Martí, Gemma
dc.contributor.author
Díaz Lorca, Maria Alba
dc.contributor.author
Carrera Álvarez, Cristina
dc.contributor.author
Alós i Hernández, Llúcia
dc.contributor.author
Delahaye, Nicolas
dc.contributor.author
Malvehy, J. (Josep)
dc.contributor.author
Puig i Sardà, Susana
dc.date.issued
2017-04-13T12:03:13Z
dc.date.issued
2017-04-13T12:03:13Z
dc.date.issued
2016-11-01
dc.date.issued
2017-04-13T12:03:13Z
dc.identifier
1434-6621
dc.identifier
https://hdl.handle.net/2445/109682
dc.identifier
668625
dc.identifier
27101548
dc.description.abstract
BACKGROUND: BRAF and NRAS mutation detection is crucial for advanced melanoma treatment. Our aim was to evaluate how different characteristics from formalin-fixed paraffin-embedded (FFPE) samples, age of the block or DNA concentration could influence the success of BRAF and NRAS mutational screening. METHODS: DNA was obtained from 144 FFPE samples (62 primary melanoma, 43 sentinel lymph nodes [SLN] and 39 metastasis). BRAF and NRAS were sequenced by Sanger sequencing. RESULTS: Complete sequencing results were obtained from 75% (108/144) of the samples, and at least one gene was sequenced in 89% (128/144) of them. BRAF was mutated in 55% (29/53) and NRAS in 11% (5/45) of the primary melanomas sequenced. DNA concentration correlated with the tumor area used for DNA extraction (mm2) (adj p-value<0.01, r=0.73). The age of the block did not affect sequencing success. In 60% of samples kept for more than 10 years, both BRAF and NRAS were successfully sequenced. CONCLUSIONS: Preserving sufficient tumor area in FFPE blocks is important. It is necessary to keep the FFPE blocks, no matter their age, as they are necessary to decide the best treatment for the melanoma patient.
dc.format
6 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Walter de Gruyter GmbH & Co. KG.
dc.relation
Reproducció del document publicat a: https://doi.org/10.1515/cclm-2015-1048
dc.relation
Clinical Chemistry and Laboratory Medicine, 2016, vol. 54, num. 11, p. 1733-1738
dc.relation
https://doi.org/10.1515/cclm-2015-1048
dc.rights
(c) Walter de Gruyter GmbH & Co. KG., 2016
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Fonaments Clínics)
dc.subject
Melanoma
dc.subject
Tumors
dc.subject
Mutació (Biologia)
dc.subject
Melanoma
dc.subject
Tumors
dc.subject
Mutation (Biology)
dc.title
Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas.
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.